ClinicalTrials.gg
RecruitingNCT06802055Updated Jun 4, 2025

Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A

A Phase 2 interventional study of Sirolimus (Rapamune®) and Cyclosporin A (CsA) in Aplastic Anaemia, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Peking Union Medical College Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 28 studies testing cyclosporine in Anemia, Aplastic — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Anemia, Aplastic.

Planned enrollment
18th of 28
40 · median 49
Started
2025
the only one that year
Phase 2
22 of 28
4 open now
Registered
26th of 28
by date
Lead sponsor
6 of 28
Peking Union Medical College Hospital

Among the 28 studies testing cyclosporine in Anemia, Aplastic, this one is the 18th largest by planned enrollment, is the only one that started in 2025, is one of 22 in phase 2, and was the 26th registered.

Anemia, Aplastic

373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

5 of the 28 studies testing cyclosporine in Anemia, Aplastic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About cyclosporine

Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing cyclosporine in Anemia, Aplastic, or all of them as a file.
02

Study summary

This is a single center, randomized, open-label, phase II study to compare the efficacy of sirolimus combined with cyclosporin A (CsA) to sirolimus alone in Chinese subjects with aplastic anemia refractory/intolerant to CsA. The safety would also be evaluated. Patients would be randomized to receive sirolimus alone or sirolimus combined with CsA at a 1:3 ratio. Treatment with sirolimus will be started at 1-3 mg once daily orally, with a target trough blood concentration of 4-12 ng/ml. CsA will be given at 25-150 mg orally every 12 hours, with the dose adjusted based on renal function and trough concentration. For patients with normal renal function, the target trough concentration is approximately 150 ng/ml. For patients with impaired renal function, the cyclosporine A dose is reduced to 25-50 mg every 12 hours, aiming for recovery or stabilization of renal function. The hematological response rate and safety will be recorded and compared at 3 and 6 months after starting the study treatment (Week 13 and 25).

03

Conditions studied

  • Aplastic Anaemia

Browse trials for

Keywords

  • Sirolimus
  • Relapsed/refractory aplastic anemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years;
  2. Diagnosed with acquired aplastic anemia (AA), excluding congenital AA;
  3. At least one of the following criteria met at enrollment: \< 100 g/L, \< 50 × 10⁹/L, or neutrophils \< 1.0 × 10⁹/L;
  4. At enrollment, meeting at least one of the following conditions:

    ① Cyclosporine A (CsA) ineffective: (CsA) used for at least 3 months without achieving partial response (PR), or disease relapse occurred;

    ② CsA intolerant: Unsuitable for standard dose CsA treatment due to adverse events or underlying conditions.

  5. No active infections;
  6. Not pregnant or breastfeeding;
  7. Willing to sign the consent form;
  8. (ECOG) performance status score of 0-2.

Exclusion criteria

Exclusion Criteria:

  1. Pancytopenia caused by other reasons, such as myelodysplastic syndrome (MDS);
  2. Evidence of clonal hematopoietic system bone marrow diseases (e.g., MDS or acute myeloid leukemia, AML);
  3. Paroxysmal nocturnal hemoglobinuria (PNH) clone ≥ 50%;
  4. History of hematopoietic stem cell transplantation () before enrollment;
  5. Previous use of sirolimus or allergy to sirolimus;
  6. Severe adverse events to CsA in the past, making it unsuitable for reuse;
  7. Uncontrolled infection or bleeding with standard treatment;
  8. Active infections with , , or , liver cirrhosis, portal hypertension;
  9. Any concurrent within the past 5 years, except for localized basal cell carcinoma of the skin;
  10. History of thromboembolic events, myocardial infarction, or stroke (including antiphospholipid antibody syndrome), or current use of anticoagulants;
  11. Pregnant or breastfeeding women;
  12. Participation in other clinical trials within the past 3 months.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Sirolimus + cyclosporin A

    Drug: Sirolimus (Rapamune®) · Drug: Cyclosporin A (CsA)

  • Placebo comparator
    Sirolimus

    Drug: Sirolimus (Rapamune®)

Interventions

  • DrugSirolimusStudies of SirolimusSirolimus pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sirolimus 1-3 mg once daily orally, with a target trough blood concentration of 4-12 ng/ml.

  • DrugCyclosporineStudies of CyclosporineCyclosporine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cyclosporine A 25-150 mg orally every 12 hours, with the dose adjusted based on renal function and trough concentration. For patients with normal renal function, the target trough concentration is approximately 150 ng/ml. For patients with impaired renal function, the cyclosporine A dose is reduced to 25-50 mg every 12 hours, aiming for recovery or stabilization of renal function.

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR) at 3 months

    Overall Response Rate (ORR) is defined as the number of participants who meet the criteria of either complete response (CR) or partial response (PR)

    Time frame: Week 12

Secondary outcomes

  1. Overall response rate (ORR) at 6 months

    ORR will be evaluated after 6 months of treatment by measuring platelet, reticulocyte, hemoglobin, neutrophil and transfusion independence.

    Time frame: Week 24

  2. Changes in Hemoglobin in the Absence of Red Blood Cells Transfusion

    The change in hematology values (hemoglobin) were evaluated

    Time frame: Week 12

  3. Changes in Platelet in the Absence of Platelet Transfusion

    The change in hematology values (platelet) were evaluated

    Time frame: Week 12

  4. Duration of hematologic response

    Time from the date of the start of the first response to the date of first relapse defined as again meeting criteria for aplastic anemia

    Time frame: by 6 months (all patients), at 12 months (responders only)

  5. Percentage of patients with clonal evolution to myelodysplasia, PNH, and acute leukemia

    Clonal evolution to myelodysplasia is defined as a new marrow cytogenic abnormality with or without characteristic dysplastic marrow findings. Evolution to leukemia is defined as greater than 20% peripheral blood and/or marrow blasts. Evolution to paroxysmal nocturnal hemoglobinuria (PNH) is defined as a clone at baseline \< 10% that rose to greater than 50% on study.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data would be accepted upon request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: 10 years

Access criteria: Email request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2026, 12 months after the start.

Of 51 non-industry phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 111. This study's planned 12 months is below that.

Counting every sponsor, half of 59 studies reached it within 76 months; a quarter within 39 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2025
First posted
Jan 30, 2025
StartActual
Jan 25, 2025
Primary completionEst.
Jan 2026
CompletionEst.
Jan 2027
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06802055
Responsible party
Sponsor
First posted
Jan 30, 2025
Start date
Jan 25, 2025
Primary completion
Jan 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Jun 4, 2025

Study contacts

Ziwei Liu
Contact
liuzw10@163.com
+8613811615392

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion